Ozanimod

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 370 publications

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal: Journal of Crohn's & colitis

Published: May 20, 2026

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Journal: Internal medicine (Tokyo, Japan)

Published: May 17, 2026

Rational Design, Synthesis, and Biological Evaluation of Potent, Highly Selective 1,2,4-Oxadiazole-Based S1PR1 Agonists for UC Treatment.

Rational Design, Synthesis, and Biological Evaluation of Potent, Highly Selective 1,2,4-Oxadiazole-Based S1PR1 Agonists for UC Treatment.

Journal: Journal of medicinal chemistry

Published: April 17, 2026

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.

Journal: International journal of molecular sciences

Published: April 15, 2026

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

Journal: Journal of neurology

Published: March 14, 2026

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse.

Sphingosine-1-phosphate (S1P) signaling as a novel therapeutic target for alcohol abuse.

Journal: Research square

Published: February 27, 2026

Real-world experience of ozanimod in adults with multiple sclerosis.

Real-world experience of ozanimod in adults with multiple sclerosis.

Journal: Neurodegenerative disease management

Published: January 30, 2026

Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone.

Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone.

Journal: Neuropharmacology

Published: January 22, 2026

Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone.

Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone.

Journal: Neuropharmacology

Published: January 22, 2026

Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds.

Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 12, 2026

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Ozanimod (ZEPOSIA®)

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Ozanimod (ZEPOSIA®)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: January 04, 2026

Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature.

Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature.

Journal: Multiple sclerosis and related disorders

Published: January 03, 2026

Showing 1-12 of 370

Last Updated: 06/30/2026